Suzanne L. Wolden, MD, FACR
Radiation Oncologist
My Role at MSKWe post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
Areas of Expertise
My Specialties
- Pediatric Radiation Oncology
- Proton Therapy
- Intensity Modulated Radiation Therapy
About Me
- Director, Pediatric Radiation Oncology
Since 1998, I have been the Director of Pediatric Radiation Oncology on the MSK Kids team who cares for children and young adults with cancer. I am a member of the pediatric, ophthalmic, and bone marrow transplant disease management teams at MSK and work very closely with other doctors in these specialties.
I have extensive experience treating rare diseases in young people such as sarcomas, brain tumors, neuroblastoma, Wilms’ tumor, lymphoma, and leukemia. Radiation therapy is an extremely powerful tool for these tumors, but young patients are especially sensitive to long-term side effects. I therefore approach each patient as a unique individual, carefully designing a highly customized radiation therapy plan to maximize the benefits of treatment while minimizing side effects.
I am a leader in the use of targeted approaches such as proton therapy, intensity-modulated radiation therapy, image-guided radiation therapy, and intra-operative radiation therapy for pediatric cancers.
Read more
In the Brain Tumor Center, I treat all children and teenagers with cancers of the brain and spinal cord (central nervous system). My clinical research has led to changes in our approach to the treatment of tumors such as medulloblastoma and central nervous system germ cell tumors. We are very mindful of patients’ long-term quality of life and seek to maintain the highest possible survival rates while minimizing the risk of potential long-term treatment complications.
I am involved in numerous clinical trials and oversee large international studies for the Children’s Oncology Group in the areas of soft-tissue sarcoma and Hodgkin lymphoma. I am involved with research on the late effects of radiation therapy through my collaboration with the Childhood Cancer Survivor Study.
I find it very rewarding to work with a team that couples extraordinary experience with compassion to care for patients with cancer. I am optimistic that our ongoing research will lead to higher cure rates as well as improved long-term quality of life for our patients.
A radiation oncologist is a cancer doctor with special training in using radiation therapy (RT) to treat cancer with radiation.
My Specialties
- Pediatric Radiation Oncology
- Proton Therapy
- Intensity Modulated Radiation Therapy
- Image-Guided Radiation Therapy
- Intra-Operative Radiation Therapy
Education
- MD, University of California San Francisco
Residencies
- Radiation Oncology - Stanford University Medical Center
Awards and Honors
- Castle Connolly: Exceptional Women in Medicine (2024)
- Castle Connolly: America’s Top Doctor (2024)
- Top Doctors New York Metro Area, Castle Connolly (2023)
- Exceptional Women in Medicine Award, Castle Connolly (2023)
- Castle Connolly: America's Top Doctors (2023)
- Castle Connolly: New York Magazine Top Doctors (2007-2020)
Board Certifications
- Radiation Oncology
Insurance Information
Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.
In Network Coverage Type
PPO
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
PPO, HMO, DSN
In Network Coverage Type
HMO, PPO
In Network Coverage Type
HMO, EPO PPO, POS
In Network Coverage Type
PPO, POS, EPO, HMO
Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.
In Network Coverage Type
PPO, HMO
In Network Coverage Type
PPO
In Network Coverage Type
HMO, EPO
Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.
In Network Coverage Type
EPO, HMO, PPO, POS
Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.
In Network Coverage Type
HMO
In Network Coverage Type
PPO
In Network Coverage Type
EPO
In Network Coverage Type
EPO
In Network Coverage Type
Federal Government
In Network Coverage Type
PPO, POS, EPO, HMO
In Network Coverage Type
State Government
Don't see your carrier or plan? We can help you understand your coverage.
If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.
If you have questions about insurance, call us at 646-497-9176.
Make an Appointment
Contact and Location
Dr. Wolden sees patients at one location.
Looking to see a doctor at a different location? See all MSK locations.
Colleagues
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
See all External Beam Radiotherapy Service, Manhattan doctors
Clinical Trials
- Clinical Trials Co-Investigated by Dr. Wolden
- A Feasibility Study of the Optune Electric Field Device to Treat Children with Recurrent or Persistent Supratentorial High-Grade Gliomas and Ependymomas
- A Phase 3 Study of Inotuzumab Ozogamicin and Standard Chemotherapy for Newly Diagnosed High-Risk B-Cell Acute Lymphocytic Leukemia, Mixed Acute Leukemia, and Disseminated B-LLy
- A Phase 3 Study of Memantine to Protect the Brain in Children Receiving Radiation Therapy for a Brain Tumor
- A Phase I/II Study of Selinexor and Radiation Therapy for Newly Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma and High-Grade Glioma
Read more
- A Phase II Study of 131I-Omburtamab plus Radiotherapy in People with Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
- A Phase II Study of Chemotherapy Followed by Radiation Therapy for Children and Young Adults with Localized Non-Germinomatous Germ Cell Tumors of the Brain or Spinal Cord
- A Phase II Study of Combination Chemotherapy, Surgery, and Radiation Therapy for Patients with High-Risk Wilms' Tumors
- A Phase III Study Comparing Standard Chemotherapy to Treatment with CPX-351 and/or Gilteritinib for Children Newly Diagnosed with Acute Myeloid Leukemia
- A Phase III Study of Different Treatments for People Newly Diagnosed with Very Low-Risk and Low-Risk Rhabdomyosarcoma
- A Phase III Study of Nivolumab in Combination with Chemo-Immunotherapy to Treat Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
- A Phase III Study to Compare Early Use of Vinorelbine and Maintenance Therapy for People with High-Risk Rhabdomyosarcoma
- A Study of How Proton Beam Radiotherapy Affects Brain Function and Quality of Life in Children and Young Adults Undergoing Treatment for a Brain Tumor
- A Study of Oral Minoxidil to Treat Hair Loss in Children and Teens Who Are Cancer Survivors
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Search clinical trialsResearch and Publications
Visit PubMed for a full listing of Dr. Wolden’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
See all on PubMedPatient Reviews
Your trust is our main concern
We strive to keep reviews trustworthy, honest and fair. Learn more about our patient experience reviews.
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Suzanne L. Wolden discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].